Compare Cassava Sciences Inc (FLNA) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs The Coca-Cola Co K — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while The Coca-Cola Co K trades at $84.75 (market cap $354.74B). The key difference: The Coca-Cola Co K is far larger — about 6675.6× Cassava Sciences Inc's market cap, and The Coca-Cola Co K pays a 2.57% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | KO | |
|---|---|---|
Market Cap | $53.14M | $354.74B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $84.25 |
52-Week Low | $1.09 | $65.67 |
Enterprise Value | -$33.43M | $384.81B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Coca-Cola (KO) trades at $84.73, up 1.99% today, with a bullish technical outlook and strong institutional buying interest. The stock shows robust fundamentals with a 27.8% net income margin and consistent earnings beats in recent quarters. Recent news highlights steady demand trends and dividend reliability, supported by a 60.42% analyst buy rating and a $89.75 consensus price target.
The outlook remains positive given KO's earnings momentum and dividend stability, though valuation multiples like a P/E of 25.93 suggest premium pricing. Risks include regional demand volatility and high debt levels. Upside potential exists if the company meets Q2 2026 EPS expectations of $0.92, aligning with analyst targets near $90.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
